ClinicalTrials.gg
RecruitingNCT05458219Updated May 4, 2026

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

A Phase 1 interventional study of IBI343 and FOLFIRINOX/mFOLFIRINOX in Locally Advanced Unresectable or Metastatic Solid Tumors, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 39 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
470
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase Ia/Ib, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, PK, and efficacy of IBI343 in participants with locally advanced unresectable or metastatic solid tumors. It is planned to be carried out in different countries or regions such as China, Australia and US.

There are three parts in phase Ia. Part 1 includes dose escalation and expansion phase and part 2 is designed for dose optimization for IBI343 monotherapy.

Part 3 1L G/GEJ AC and 1L PDAC cohorts will include an initial safety lead-in stage to confirm the tolerability of IBI343 in combination with chemotherapy in 1L PDAC and G/GEJ AC, followed by a randomized dose-optimization stage designed to further characterize safety, pharmacokinetics, and preliminary efficacy to inform selection of the recommended Phase 3 dose.

02

Conditions studied

  • Locally Advanced Unresectable or Metastatic Solid Tumors
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion criteria to be met for both Phase Ia and Phase Ib:

  1. Has signed written Form (ICF), willing and able to comply with protocol-specified visits and related procedures.
  2. Phase Ia dose escalation phase, Phase Ia part 3 1L G/GEJ AC and 1L PDAC cohorts Safety Lead-in stage: Has at least 1 evaluable lesion according to v1.1; Phase Ia dose expansion and dose optimization phase, Phase Ia part 3 1L G/GEJ AC and 1L PDAC cohorts Dose optimization stage, Phase Ib: Has at least 1 according to Response Evaluation Criteria in Solid Tumors RECIST v1.1.
  3. Age ≥ 18 years, of either sex.
  4. Has an (ECOG) performance status (PS) of 0 or 1.
  5. Has an expected survival ≥ 12 weeks.
  6. Has adequate bone marrow and organ function. Defined as:

    • Hematology: ≥ 1.5 × 109/L; count ≥ 100 × 109/L; ≥ 9.0 g/dL, participants must not have received transfusion of blood products (including red blood cell suspension, apheresis platelets, cryoprecipitate, etc.), erythropoietin (EPO), G-colony stimulating factor (G-CSF) or granulocyte-macrophage colony stimulating factor (GM-CSF) within 7 days prior to blood sample collection;
    • Hepatic function: ≤ 1.5 × (TBIL ≤ 3 × ULN is allowed for participants with Gilbert's syndrome); and AST ≤ 2.5 × ULN for participants without liver and ≤ 5 × ULN for participants with liver metastasis; Albumin ≥ 28 g/L;
    • Renal function: estimated ≥ 30mL/min (using Appendix 5. Calculation of Estimated Creatinine Clearance and Body Surface ).
    • Coagulation function: (INR) ≤ 1.5 and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (participants receiving anticoagulant therapy with coagulation function within the above range are allowed).
  7. Female participants of or male participants whose partners are female of childbearing potential are required to use effective measures throughout the treatment period and for 6 months after the final treatment period.

Inclusion Criteria for Phase Ia Dose Escalation:

  1. Participants with histopathologically confirmed unresectable locally advanced or metastatic malignant solid tumors that have failed or were intolerant to standard therapy or for whom no standard therapy is available.

Inclusion Criteria for Phase Ia Dose Expansion, Dose Optimization :

  1. Participants with histopathologically confirmed unresectable locally advanced or metastatic G/GEJ AC, PDAC, BTC, or other solid tumors who have failed or were intolerant to standard therapy or for which no standard therapy is available.
  2. * CLDN18.2-positive confirmed by pathological examination (in dose expansion phase, G/GEJ AC and PDAC preferentially enrolled *** moderate to high expression of CLDN18. 2; in dose optimization phase , G/GEJ AC preferentially enrolled **high expression of CLDN18.2 and PDAC preferentially enrolled ***moderate to high expression of CLDN18.2). For participants with previous anti-CLDN18.2 treatment (including but not limited to monoclonal antibodies, ADCs, CAR-T, etc.), tumor samples should be obtained post anti-CLDN18.2 therapy for CLDN18.2 expression evaluation.

Inclusion Criteria for Phase Ia Part 3 1L G/GEJ AC Cohort:

  1. Participants with histopathologically confirmed unresectable locally advanced or metastatic G/GEJ AC who has not received previous systemic therapy. (For Safety Lead-in stage, participants who has received previous systemic therapy are permitted.) A prior (neo) systemic therapy completed within 6 months prior to disease relapse or progression will be considered as having received previous systemic therapy.
  2. Confirmed Her 2-negative (defined as IHC 0 or 1+, or IHC 2+ and negative by in situ hybridization) disease.
  3. Confirmed combined positive score (CPS) \<5 as determined by local IHC testing.
  4. Participants must not have previously received topoisomerase inhibitor-based antibody-drug conjugate(s), unless given peri-operatively without evidence of resistance.
  5. Participants must not have previously received anti-CLDN18.2 therapy.
  6. *CLDN18.2-positive confirmed by pathological examination by central laboratory (For Dose optimization stage, G/GEJ AC enrolled participants with Claudin18.2 immunohistochemical membrane staining intensity 2+/3+ in ≥50% of tumor cells).

Inclusion Criteria for Phase Ia Part 3 1L PDAC Cohort:

  1. Participants with histopathologically confirmed metastatic PDAC who has not received previous systemic therapy in the metastatic setting. (For Safety Lead-in stage, participants who has received previous systemic therapy are permitted.) A prior (neo)adjuvant systemic therapy completed within 12 months prior to disease relapse or progression will be considered as having received previous systemic therapy.
  2. Participants must not have previously received anti-CLDN18.2 therapy.
  3. Participants must not have previously received topoisomerase inhibitor-based antibody-drug conjugate(s), unless given peri-operatively without evidence of resistance.
  4. *CLDN18.2-positive confirmed by pathological examination by central laboratory (For Dose optimization stage, PDAC enrolled # specified expression of CLDN 18.2)

Inclusion Criteria for Phase Ib Cohort A:

  1. Histopathologically confirmed unresectable locally advanced or metastatic G/GEJ AC.
  2. Have received at least 2 [anti-PD-(L)1 + platinum, fluoropyrimidines, paclitaxel/docetaxel, or irinotecan; participants with overexpression (defined as 3 + or 2 + by immunohistochemistry and ISH +) must have received anti-HER2 therapy, and participants who have not received prior anti-PD-(L)1 or anti-HER2 therapy must have had a or reasonable reason for no benefit] and have had disease progression.
  3. High expression of **CLDN18. 2 was confirmed by pathological examination.

Inclusion Criteria for Phase Ib Cohort B:

  1. Histopathologically confirmed unresectable locally advanced or metastatic G/GEJ AC.
  2. Disease progression after first-line standard therapy (HER2-overexpressing participants must have received prior anti-HER2 therapy unless contraindicated or justified non-benefit).
  3. Confirmed * CLDN18.2-positive by histopathological examination.

Inclusion Criteria for Phase Ib Cohort C:

  1. Histopathologically confirmed unresectable locally advanced or metastatic PDAC.
  2. Disease progression after at least one prior systemic therapy.

Inclusion criteria for Phase Ib Cohort D:

  1. Histopathologically confirmed unresectable locally advanced or metastatic BTC.
  2. Disease progression after at least one prior systemic therapy.
  3. Confirmed * CLDN18.2-positive by histopathological examination.

Notes:

  • CLDN18.2-positive: defined as ≥ 1% of tumor cells with membranous staining of any intensity in tumor tissue by immunohistochemistry, when tested previously, at the study site, or at the central laboratory.

    • High expression of CLDN18. 2: Claudin18.2 immunohistochemical membrane staining intensity ≥ 2 + in ≥ 75% of tumor cells.

      • Moderate to high expression of CLDN18.2: Claudin18.2 immunohistochemical membrane staining intensity ≥ 2 + in ≥ 40% of tumor cells.

        • Specified expression of CLDN18.2: Claudin18.2 immunohistochemical membrane staining intensity 1+/2+/3+ in ≥50% of tumor cells.

Exclusion Criteria:

Exclusion criteria common to Phases Ia and Ib:

  1. Is participating in another interventional clinical study other than an observational (non-interventional) clinical study or is in the survival follow-up phase of an interventional study.
  2. Has received the last dose of antineoplastic therapy within 4 weeks or 5 half-lives of an antineoplastic therapy (whichever is shorter) prior to the first dose of study drug.
  3. Plans to receive other anti-tumor therapy during treatment with the study drug [palliative radiotherapy for symptomatic relief (e.g., pain) that does not affect response assessment is allowed].
  4. Has received a strong cytochrome P450 3A4 () inhibitor within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of study drug.
  5. Toxicities due to prior therapy that have not recovered to Grade 0 or 1 per v5.0 prior to the first dose of study drug (excluding alopecia, asthenia, hyperpigmentation, and other conditions with no safety risk per the judgment of the investigator).
  6. Has undergone major surgical procedure (craniotomy, thoracotomy, laparotomy or others per the investigator, excluding needle ) or has unhealed wounds, ulcers, or bone fracture within 4 weeks prior to the first dose of study drug; Or plans to undergo major surgery during the study period; Note: Local surgical treatment of isolated lesions for palliative purposes is acceptable.
  7. Has gastric pyloric obstruction and/or persistent recurrent vomiting (≥ 3 episodes in 24 hours).
  8. Has a history of gastrointestinal perforation and/or fistula within 6 months that has not resolved surgically prior to the first dose of study drug.
  9. Has symptomatic central nervous system metastases. Participants with asymptomatic (i.e., no neurological symptoms, no need for treatment, all brain metastasis ≤ 1. 5 cm) or stable symptoms after treatment of brain metastases must meet all of the following criteria to participate in the study: no metastasis in the midbrain, pons, cerebellum, meninges, medulla oblongata or spinal cord; Stable clinical status for at least 4 weeks with definitive clinical evidence of no new or enlarging brain metastasis and discontinuation of corticosteroids and anticonvulsants for at least 2 weeks prior to the first dose of study drug. Note: lesions of the central nervous system will not be considered as a target lesion
  10. Has a history of pneumonitis requiring corticosteroids therapy, or a history of interstitial lung disease, non-infectious pneumonitis, severely impaired lung function or uncontrolled lung disease, such as pulmonary fibrosis, severe radiation pneumonitis, acute lung injury, or suspected of having the above diseases during the screening period.
  11. Has uncontrolled medical conditions, such as:
  12. Active or clinically uncontrolled serious infection requiring treatment with systemic anti-infectives (antibiotics, antivirals, or antifungals) within 1 week prior to the first dose of study drug, including but not limited to the infection of respiratory tract, urinary system, biliary tract infection, etc.
  13. Participants infected with (HIV) (HIV 1/2 antibody positive).
  14. Acute or chronic active (defined as hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody positive (HBcAb) with hepatitis B virus DNA copies ≥ 104 copies/mL or ≥ 2000 IU/mL or above the lower limit of detection) or acute or chronic active [hepatitis C virus antibody (HCVAb) positive with HCV RNA > 103 copies/mL]. Participants whose test results are below the above criteria after receiving antiviral therapy with nucleotides, or participants with positive serology but negative HCV-RNA test result are eligible.
  15. Has active pulmonary tuberculosis, is being treated with anti-tuberculosis therapy or having received anti-tuberculosis therapy within 1 year prior to the first dose of study drug.
  16. Has active syphilis or latent syphilis requiring treatment.
  17. Has symptomatic congestive heart failure ( classification NYHA class II-IV), symptomatic or uncontrolled arrhythmia, > 480 ms, or personal or family history of congenital long/short QT syndrome.

    For part 3 1L G/GEJ AC and 1L PDAC cohort, the QTc should be calculated based on the average of triplicate screening (using Appendix 4 Calculation Formula of QTcF)

  18. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg) by standard treatment.
  19. Has one or more arterial thromboembolic event, including myocardial infarction, unstable angina, cerebrovascular accident, , etc., within 6 months prior to the first dose of study drug.
  20. Has received stent implantation in tracheal or digestive tract.
  21. Has symptomatic pleural, ascites, or pericardial effusion requiring intervention (e.g., drainage, peritoneal shunt, or cell-free and concentrated ascites reinfusion therapy [CART]). Asymptomatic participants with a small amount of pleural effusion, ascites or pericardial effusion on imaging are allowed. (Drainage and CART are not allowed within 2 weeks prior to screening assessment).
  22. Has esophageal or gastric varices that require immediate intervention (e.g., ligature or sclerotherapy) or are considered to be at high risk for bleeding in the opinion of the investigator or consulting gastroenterologist or hepatologist. Participants with evidence of portal hypertension (including splenomegaly on imaging) or a history of prior variceal bleeding must undergo endoscopic evaluation within 3 months prior to the first dose of study drug.
  23. Has one or more life-threatening bleeding event or Grade 3 or 4 gastrointestinal/variceal bleeding requiring blood transfusion, endoscopic or surgical treatment within 3 months prior to the first dose of study drug
  24. Has a history of deep vein thrombosis, pulmonary embolism, or any other serious venous thromboembolism within 3 months prior to the first dose of study drug (implantable venous access port or catheter-derived thrombosis, or superficial vein thrombosis is not considered "serious" venous thromboembolism).
  25. Has hepatic encephalopathy, hepatorenal syndrome, or B or more severe cirrhosis.
  26. Has complete or incomplete intestinal or bowel obstruction at the time of screening or a history of complete or incomplete intestinal or bowel obstruction within 3 months prior to first dose, or is at risk of intestinal perforation (including but not limited to acute diverticulitis, history of intra-abdominal abscess), or a history of any of the following disease: inflammatory bowel disease or extensive bowel resection (partial colectomy or extensive small bowel resection with concurrent chronic diarrhea), Crohn's disease, ulcerative colitis, and chronic diarrhea.
  27. Has other acute or chronic disease or laboratory abnormality that may result in increased risk associated with study participation or study drug administration, or interfere with the interpretation of study results, and is considered unfit for this study per the Investigator's judgement.
  28. Has a neurological or psychiatric illness or a social situation that affects compliance with study requirements, significantly increases the risk of AE, or affects the participant's ability to provide written ICF.
  29. Has a history of other primary , with the following exceptions:
  30. Curatively treated malignancy with no known active disease for ≥ 2 years prior to study enrollment and is at minimal risk of recurrence;
  31. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease recurrence;
  32. Adequately treated carcinoma in situ with no evidence of disease recurrence.
  33. Has a known history of immunodeficiency.
  34. Has a history of allogeneic organ transplantation and history of hematopoietic stem cell transplantation.
  35. Has a history of severe allergic reaction to other monoclonal antibodies and/or to any of the formulation components of IBI343 or mFOLFOX or Irinotecan or liposomal Irinotecan (For phase 1a part 3 1L G/GEJ AC and 1L PDAC cohort).
  36. Female participants who are pregnant or lactating.
  37. Has other conditions considered not eligible to participate in this study per the Investigator's judgement.
  38. Has known dihydropyrimidine dehydrogenase deficiency (DPD). (NOTE: Screening for DPD deficiency should be conducted per local requirements.)
  39. Has known peripheral sensory neuropathy > grade 1 unless the absence of deep tendon reflexes is the sole neurological abnormality.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
470 participants (estimated)

Study arms

  • Experimental
    3 arms

    Phase 1a Part 3: For monotherapy: 6 mg/kg Q3W was confirmed as the optimal dosing regimen for balancing clinical benefits and potential risks. In 1L G/GEJ AC and 1L PDAC cohort of the Phase Ia (Part 3) study, IBI343 combination therapy is proposed to be administered at doses of 4 mg/kg (Dose level 1) Q2W or 5 mg/kg (Dose level 2) Q2W in participants with G/GEJ AC and PDAC for the randomized study.

    Drug: FOLFIRINOX/mFOLFIRINOX · Drug: mFOLFOX · Drug: IBI343

  • Experimental
    Single arm

    Phase 1a Part 1 Dose Escalation: IBI343 will be administered intravenously (IV) at different dose levels following traditional 3+3 dose escalation design for following levels. Phase 1a Part 1 Dose Expansion: IBI343 will be administered at dose levels which is equal or lower than MTD. Each dose level contains no more than 30 subjects (including subjects in dose escalation) Phase 1a Part 2 Dose Optimization: IBI343 will be administered in parallel cohorts (randomized 1:1 ratio) to determine the optimal dose for the PDAC indication across China, Australia and the US (n=40). Dose levels 4.5mg/kg and 6mg/kg will be studied. Phase 1b Dose Extension: IBI343 will be administered at RP2D.

    Drug: IBI343

Interventions

  • DrugIBI343

    IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.

  • DrugFOLFIRINOX/mFOLFIRINOX

    Drug page: Folfirinox

    FOLFIRINOX/mFOLFIRINOX will be administered IV Q2W on Days 1-3 every 2 weeks (14 days).

  • DrugmFOLFOX

    mFOLFOX will be administered IV Q2W on Days 1-3 every 2 weeks (14 days) in each cycle after IBI343

  • DrugIBI343

    IBI343 will be administered IV Q2W on Day1 (14 days).

06

What researchers measure

Primary outcomes

  1. Adverse events(AEs), treatment emergent adverse event (TEAEs),serious adverse events (SAEs)

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0.

    Time frame: Up to 90 days after the last administration

  2. Dose-limiting Toxicity (DLT)

    DLTs are assessed during the DLT observation period to determine maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

    Time frame: 21 days after the first dose of IBI343

  3. To determine RP2D of IBI343.

    To determine RP2D of IBI343.

    Time frame: Up to 2 years

  4. ORR assessed by the investigator based on RECIST version 1.1.

    ORR assessed by the investigator based on RECIST version 1.1.ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR)

    Time frame: Up to 2 years

  5. Number of subjects with clinically significant changes in physical examination results

    A complete physical examination will include: general appearance, respiratory, cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose, and pharynx), lymph nodes, thyroid, musculoskeletal (including spine and extremities), genital/anal, and neurological assessments, if indicated. Clinically significant abnormal findings at screening will be recorded as medical history or AE based on the investigator's analysis and judgment.

    Time frame: Up to 2 years

  6. Number of participants with abnormal vital signs

    Collection of vital signs will include temperature in ℃, measurement tool is physiological parameter

    Time frame: Through study completion, up to 2 years

  7. Objective response rate (ORR)

    Through study completion, up to 2 years

    Time frame: ORR is defined as the proportion of participants with a completeresponse (CR) or partial response (PR)

  8. Number of participants with abnormal laboratory tests results

    Blood routine:RBC, HGB, HCT, WBC, PLT, LYM, ANC

    Time frame: Through study completion, up to 2 years

  9. Number of participants with abnormal vital signs

    Collection of vital signs will include pulse in beats per minute. measurement tool is physiological parameter

    Time frame: Through study completion, up to 2 years

  10. Number of participants with abnormal vital signs

    Collection of vital signs will include respiratory rate in times/min. measurement tool is physiological parameter

    Time frame: Through study completion, up to 2 years

  11. Number of participants with abnormal vital signs

    Collection of vital signs will include blood pressure in kPa. measurement tool is physiological parameter

    Time frame: Through study completion, up to 2 years

  12. Number of participants with abnormal laboratory tests results

    Blood biochemistry: TBIL, DBIL, ALT, AST, γ-GGT, ALP, ALB, TP, LDH, Urea or BUN, Cr, Na, K, Cl, Mg, Ca, P, Amylase, Lipase and FBG

    Time frame: Through study completion, up to 2 years

  13. Number of participants with abnormal laboratory tests results

    Urinalysis: PH, Specific Gravity, UWBC, UPRO, URBC, UGLU, UBLD

    Time frame: Through study completion, up to 2 years

  14. Number of participants with abnormal laboratory tests results

    Coagulation function: APTT, PT, INR, Fbg, D-dimer

    Time frame: Through study completion, up to 2 years

  15. Number of participants with abnormal laboratory tests results

    Viral serology test: HBsAg, HBsAb, HBcAb, HBeAg, HBeAb, HBV DNA, HCV antibody, HCV RNA, HIV antibody, Treponema pallidum-specific antibody

    Time frame: Through study completion, up to 2 years

  16. Number of participants with abnormal laboratory tests results

    Myocardial injury markers: CK, CK-MB, Troponin I or T, BNP or NT-proBNP

    Time frame: Through study completion, up to 2 years

  17. Number of participants with abnormal laboratory tests results

    Fecal analysis: occult blood (OB)

    Time frame: Through study completion, up to 2 years

Secondary outcomes

  1. maximum concentration (Cmax)

    PK parameters maximum concentration (Cmax) of IBI343, total antibody, can will be determined.

    Time frame: Up to 2 years

  2. area under the curve (AUC)

    PK parameters area under the curve (AUC) of IBI343, total antibody, exatecan will be determined.

    Time frame: Up to 2 years

  3. clearance rate (CL)

    PK parameters clearance rate of IBI343, total antibody, exatecan will be determined .

    Time frame: Up to 2 years

  4. half-life (t1/2)

    PK parameters half-life (t1/2) of IBI343, total antibody, exatecan will be determined .

    Time frame: Up to 2 years

  5. Anti-drug antibody(ADA) of IBI343

    The incidence and characterization of ADA of IBI343 will be determined

    Time frame: Up to 2 years

  6. Objective response rate (ORR)

    ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR).

    Time frame: Through study completion, up to 2 years

  7. time to response (TTR)

    TTR is defined as the time from the date of first dose of study drug to the date of first documented tumor response (CR/PR).

    Time frame: Through study completion, up to 2 years

  8. duration of response (DoR)

    DoR is defined as the time from the date of first documented tumor response (CR/PR) until PD/death.

    Time frame: Through study completion, up to 2 years

  9. disease control rate (DCR)

    DCR is defined as the proportion of participants with a complete response (CR) or partial response (PR) or stable disease(SD)

    Time frame: Through study completion, up to 2 years

  10. progression-free survival (PFS)

    PFS is defined as the time from the date of first dose of study drug to the date of the first documented progression or death due to any cause, whichever occurs first.

    Time frame: Through study completion, up to 2 years

  11. Overall survival (OS)

    OS is defined as the time from the date of first dose of study drug until the date of death from any cause.

    Time frame: Through study completion, up to 2 years

  12. apparent volume of distribution (V)

    PK parameters apparent volume of distribution(V) of IBI343, total antibody, exatecan will be determined when appropriate.

    Time frame: Up to 2 years

  13. Tmax

    PK parameters time to maximum concentration of IBI343, total antibody, exatecan will be determined when appropriate.

    Time frame: Up to 2 years

  14. assess the immunogenicity of IBI343.

    The incidence of ADA.

    Time frame: Up to 2 years

  15. To evaluate the correlation between CLDN18.2 expression level in tumor tissue and anti-tumor activities of IBI343 combination therapy.

    Baseline CLDN18.2 expression level and relationship with efficacy.

    Time frame: Up to 2 years

  16. To evaluate the correlation between CLDN18.2, PD-L1, HER2 expression level in tumor tissue in 1L G/GEJ AC cohort.

    Baseline CLDN18.2, PD-L1, HER2 expression level and their correlation in 1L G/GEJ AC cohort.

    Time frame: Up to 2 years

07

Study locations

38 of 39 sites recruiting
  • Next Oncology-Austin
    Austin, Texas 78758, United States
    Recruiting
    • Sheena Sahota · Principal investigator
  • Next Oncology-Dallas
    Irving, Texas 75039, United States
    Recruiting
    • Shiraj Sen · Principal investigator
  • Next Oncology-San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Ildefonso I Rodriguez Rivera · Principal investigator
  • St Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
    Recruiting
  • Cancer Care Wollongong
    Wollongong, New South Wales 2500, Australia
    Recruiting
    • Gary Tincknell, Dr · Principal investigator
  • Pindara Private Hospital
    Benowa, Queensland 4217, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sunshine Coast University Private Hospital
    Birtinya, Queensland 4575, Australia
    Recruiting
  • Anhui Cancer Hospital
    Hefei, Anhui, China
    Recruiting
    • Suyi Li · Principal investigator
  • Anhui Provincial Hospital
    Hefei, Anhui, China
    Recruiting
    • Yueyin Pan · Principal investigator
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui, China
    Recruiting
    • Lili Sheng · Principal investigator
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • Lin Shen · Principal investigator
  • Tumor Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality, China
    Recruiting
    • Aiping Zhou · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
    Recruiting
    • Jianwei Yang · Principal investigator
  • Sun Yat-sen Memorial Hospital Sun Yat-Sen university
    Guangzhou, Guangzhou, China
    Recruiting
    • Zhihua Li · Principal investigator
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangzhou, China
    Recruiting
    • Xiaoyu Yin · Principal investigator
  • Henan Provincial People&#39;s Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Chuangxin Lu · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
    Recruiting
    • Yanru Qin · Principal investigator
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
    Recruiting
    • Xinjun Liang · Principal investigator
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog
    Wuhan, Hubei, China
    Recruiting
    • Xianglin Yuan · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan, China
    Recruiting
    • Zhenyang Liu · Principal investigator
    • YongChang Zhang · Principal investigator
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Juan Du · Principal investigator
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi, China
    Recruiting
    • Rongfeng Song · Principal investigator
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
    Recruiting
    • Jianbing Wu · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
    Recruiting
    • Xiujuan Qu · Principal investigator
  • Ningxia Medical University General Hospital
    Yinchuan, Ningxia, China
    Recruiting
    • Ping Chen · Principal investigator
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi, China
    Recruiting
    • Enxiao Li · Principal investigator
  • Jinan Central Hospital
    Jinan, Shandong, China
    Recruiting
    • Meili Sun · Principal investigator
  • Shandong Cancer Hospital
    Jinan, Shandong, China
    Recruiting
    • Yuping Sun · Principal investigator
    • Jinbo Yue · Principal investigator
  • Jining First People&#39;s Hospital
    Jining, Shandong, China
    Recruiting
    • Jie Li · Principal investigator
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
    Recruiting
    • Zimin Liu · Principal investigator
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Xianjun Yu · Principal investigator
  • Renji Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Xiuying Xiao · Principal investigator
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Jun Zhang · Principal investigator
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
    Recruiting
    • Xuelei Ma · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting
    • Ting Deng · Principal investigator
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Jian Ruan · Principal investigator
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
    Recruiting
    • Jieer Ying · Principal investigator
  • Zhejiang Provincial People&#39;s Hospital
    Hangzhou, Zhejiang, China
    Recruiting
    • Yiping Mou · Principal investigator
  • Ningbo Medical Center Li Huili Hospital
    Ningbo, Zhejiang, China
    Recruiting
    • Yongfei Hua · Principal investigator
    • Weiming Yu · Principal investigator
08

References and documents

Publications

  • Liu J, Yang J, Sun Y, Gong J, Yue J, Pan Y, Sun M, Song R, Xiao X, Tazbirkova A, Ruan J, Liu Z, Liu Z, Li Z, Sheng L, Qin Y, Ying J, Yu X, Zhang J, Mou Y, Lu C, Chen P, Li S, Li J, Qu X, Deng T, Du J, Zhou A, Li E, Yuan X, Liang X, Yu W, Morris M, Luo Y, Zhao X, Guo Y, Zhou H, Shen L. CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med. 2025 Sep;31(9):3028-3036. doi: 10.1038/s41591-025-03783-8. Epub 2025 Jul 16. PubMed 40670773 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Jun 2027, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2022
First posted
Jul 14, 2022
StartActual
Oct 26, 2022
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05458219
Collaborators
Fortvita Biologics (USA)Inc., TigerMed
Responsible party
Sponsor
First posted
Jul 14, 2022
Start date
Oct 26, 2022
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 4, 2026

Study contacts

Suhua Dong
Contact
suhua.dong@innoventbio.com
0512-69566088

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arcotatug tavatecan

Start the discussion